DRSP (DROSPIRENONE) LAWSUITS SETTLEMENTS UPDATE APRIL 2012:
BLOOMBERG REPORTS YASMIN YAZ BEYAZ SAFYRAL SETTLEMENTS CLIMB TO $142 MILLION AS OF APRIL 19, 2012
On April 26, 2012, BLOOMBERG reported that BAYER’s YAZ YASMIN SETTLEMENTS involving DRSP (DROSPIRENONE) had climbed to $142 Million U.S. Dollars as of April 19, 2012. In “BAYER YASMIN LAWSUIT SETTLEMENTS CLIMB TO $142 MILLION“, J. Feeley and M. Cronin Fisk cite to a “Stockholder’s Letter” published by BAYER to confirm nearly 700 settlements as of April 19, 2012. This story supplements a prior, April 13, 2012, story that cited $110 Million U.S. Dollars in settlements. That announcement came only days after the U.S. Food & Drug Administration (“FDA“) announced it was finally acting on the December 8, 2011, recommendation of experts to revise the safety labeling for DRSP (DROSPIRENONE) containing birth control pills. The revised warning labels include data from numerous studies confirming the birth control pills are higher risk and potentially present a 3x higher chance of blood clots. FDA’s own study, published in October 2011, confirmed a 74% higher risk, among other things.
Prior stories would not confirm settlement amounts or figures. The “Stockholder’s Letter” confirms settlements and notes that they are ongoing and on a rolling basis. As such, DROSPIRENONE LAWSUITS or DRSP LAWSUITS are in fact being evaluated on a “case by case basis” with consideration given to the medical records and outcome of each individual. Analyst have estimated, according to BLOOMBERG, that BAYER’S liability may approach $2.65 BILLION U.S. DOLLARS over the Blockbuster family of contraceptives that include the trademarked: YASMIN, YAZ, BEYAZ & SAFRYAL, as well as well known generics OCELLA, GIANVI, ZARAH & SEYEDA.
Any girl or woman that suffered a Heart Attack, Myocardial Infarction, Stroke, Pulmonary Embolism, Deep Vein Thrombosis or complication from blood clots may be entitled to monetary compensation for their injuries and damages. Since 2009, multiple studies have confirmed that DROSPIRENONE (DRSP) presents a higher risk of blood clots to users than other forms of birth control. Recent label changes arguably confirm that the pills have never carried the proper warning for over a decade and may lead to even more lawsuits as unknowing victims come forward seeking redress for their blood clotting injuries.
FREE CASE EVALUATIONS ARE AVAILABLE FROM THE SPONSOR OF THIS SITE THROUGH USE OF THE CONTACT FORM BELOW.